PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
12.93%
G&A growth while GNPX reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses change of 5.37% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
14.34%
Operating expenses growth while GNPX reduces costs. John Neff would investigate differences.
14.34%
Total costs growth while GNPX reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A growth less than half of GNPX's 178.97%. David Dodd would verify if efficiency is sustainable.
-16.61%
EBITDA decline while GNPX shows 24.84% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Operating income decline while GNPX shows 24.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Other expenses reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine advantage.
-20.40%
Pre-tax income decline while GNPX shows 24.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Net income decline while GNPX shows 24.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
EPS decline while GNPX shows 57.19% growth. Joel Greenblatt would examine position.
-20.61%
Diluted EPS decline while GNPX shows 57.14% growth. Joel Greenblatt would examine position.
0.76%
Share count reduction exceeding 1.5x GNPX's 75.85%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.